During the Super Bowl, Hims & Hers Health aired a commercial called “Sick of the System.” But before the 60-second spot was ...

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

Today, Hims offers a variety of medications and treatment options for men seeking to lose weight. Men can schedule a consultation via Hims and then receive a prescription for Metformin ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last three months.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.